Efavirenz-Based Antiretroviral Therapy but Not Pregnancy Increased Unbound Piperaquine Exposure in Women during Malaria Chemoprevention-Reference-Cited by-同舟云学术

Efavirenz-Based Antiretroviral Therapy but Not Pregnancy Increased Unbound Piperaquine Exposure in Women during Malaria Chemoprevention

Published:2023-04-18 Issue:4 Volume:67 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Hong Howard¹^ORCID,Aslam-Mir Usman¹,Kajubi Richard²,Wallender Erika¹^ORCID,Mwebaza Norah²,Dorsey Grant³,Rosenthal Philip J.³^ORCID,Aweeka Francesca T.¹,Huang Liusheng¹^ORCID

Affiliation:

1. Drug Research Unit, Department of Clinical Pharmacy, University of California, San Francisco, California, USA

2. Infectious Disease Research Collaboration, Makerere University College of Health Sciences, Kampala, Uganda

3. Department of Medicine, University of California, San Francisco, California, USA

Abstract

Dihydroartemisinin-piperaquine (DP) is highly effective for malaria chemoprevention during pregnancy, but the standard dosing of DP that is used for nonpregnant adults may not be optimal for pregnant women. We previously reported that the pharmacokinetic exposure of total piperaquine (PQ; both bound and unbound to plasma proteins) is reduced significantly in the context of pregnancy or efavirenz (EFV)-based antiretroviral therapy (ART).

Funder

HHS | National Institutes of Health

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.01427-22

Reference27 articles.

1. WHO. 2021. World malaria report. WHO. https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2021.

2. The burden of malaria in pregnancy in malaria-endemic areas

3. Estimated risk of placental infection and low birthweight attributable to Plasmodium falciparum malaria in Africa in 2010: a modelling study

4. WHO. 2014. WHO policy brief for the implementation of intermittent preventive treatment of malaria in pregnancy using sulfadoxine-pyrimethamine (IPTp-SP). https://www.who.int/publications/i/item/WHO-HTM-GMP-2014.4.

5. Estimated impact on birth weight of scaling up intermittent preventive treatment of malaria in pregnancy given sulphadoxine-pyrimethamine resistance in Africa: A mathematical model